We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

MINDRAY In-Vitro Diagnostics

As a global leader in in-vitro diagnostics, Mindray provides a wide range of efficient, reliable IVD solutions for la... read more Featured Products: More products

Download Mobile App




Cutting-Edge Cardiac Biomarker Assays Enhance Cardiovascular Diseases Care

By LabMedica International staff writers
Posted on 31 Oct 2023
Print article
Image: The new cardiac biomarker assays aim to improve care of cardiovascular diseases (Photo courtesy of Mindray)
Image: The new cardiac biomarker assays aim to improve care of cardiovascular diseases (Photo courtesy of Mindray)

Heart-related diseases, or cardiovascular diseases (CVDs), are the number one cause of death across the globe. Early detection is crucial for saving lives. Medical guidelines suggest using high-sensitivity troponin I (hs-cTnI) and NT-proBNP as critical markers for identifying possible Acute Coronary Syndrome (ACS) and heart failure. These markers are essential for quick diagnosis, evaluating risk, and guiding treatment. Now, two new cutting-edge hs-cTnI and NT-proBNP assays aim to enhance the diagnosis and management of CVDs.

Mindray (Shenzhen, China) and its subsidiary HyTest, a global leader in antibodies and antigens, have collaborated to create these new assays. HyTest has been recognized for its expertise in cardiac biomarkers and had its troponin complex designated as the international standard by AACC in 2004. Both of the newly developed assays have been validated by Wuhan Asian Heart Hospital in China and Hennepin Healthcare Research Institute in the United States, showing excellent clinical performance.

The hs-cTnI test from Mindray exceeds the minimum requirements for hs-cTn, achieving an impressive 93% detection rate in the range between LoD and the 99th URL. Additionally, it has an imprecision CV under 5% at the 99th URL, proving its high sensitivity, accuracy, and dependability for spotting heart muscle damage. Moreover, a diagnostic study focusing on a 0-2 hour timeframe, carried out at Hennepin Healthcare Research Institute, supports its efficacy in diagnosing and managing heart conditions within this critical period. On the other hand, NT-proBNP is a well-established marker for heart failure management. Mindray's NT-proBNP test shows a high level of accuracy with a CV of ≤5% and successfully minimizes the impact of 55 common heart medications, making it a reliable tool for the detection and management of heart failure.

"Through integrating HyTest's pioneering antibodies and research on cardiac biomarkers with Mindray's advanced reagent technology and platform, we will deliver more reliable solutions that bring improved patient outcomes in the field of cardiovascular diseases and beyond," said Dr. Jianwen He, Chief Scientific Officer of Mindray IVD.

Related Links:
Mindray

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Liquid Ready-To-Use Lp(a) Reagent
Lipoprotein (a) Reagent

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.